The AIM-listed firm said Sederma, its partner in the cosmetics programme and a division of Croda International PLC (LON:CRDA), has successfully replicated the lysate manufacturing process and achieved the same performance from the company’s SkinBiotix technology and is now working to validate a scale up of the manufacturing process at different volume levels.
SkinBio said the project is progressing in line with the original plan and has not been impacted by the coronavirus pandemic, adding that any results from the programme will be sold to Croda's global portfolio of Personal Care customers, with the company receiving tiered royalties based on global sales revenues on any products developed in the partnership.
Meanwhile, the firm said in light of current restrictions on non-coronavirus related human studies, it has established a protocol for its ‘ self-managed’ psoriasis food supplement trial and was proceeding with the study.
Participants suffering from mild to moderate psoriasis will be invited to participate in a human study in which they will be provided with samples of AxisBiotix Ps to self-administer over eight weeks and track the impact of the food supplement on their skin condition. They will then submit their findings periodically through a bespoke mobile app, avoiding the need for clinical attendance.
SkinBio said this will accelerate the timing of readout compared to the previously envisaged conventional study, and if the findings were positive this will allow for a “significantly earlier commercial launch than originally planned”. The trial is expected to begin in early 2021.
"We have seen significant positive progress made on the first of our commercial programmes in recent weeks. In such an important scientific milestone, it is reassuring and provides validation of our approach that Sederma has been able to replicate the activity of the SkinBiotix technology and is pushing ahead with the next steps of the project”, SkinBio chief executive Stuart Ashman said in a statement.
"In addition, establishing a clear pathway to commencing a food supplement trial to manage symptoms associated with psoriasis is a great step forward for our collaboration with Winclove. The progress made in such a short period of time is testament to the combined efforts of the SkinBioTherapeutics and Winclove team", he added.